2. Academic Validation
  3. Development of Autotaxin Inhibitors: An Overview of the Patent and Primary Literature

Development of Autotaxin Inhibitors: An Overview of the Patent and Primary Literature

  • J Med Chem. 2016 Jun 23;59(12):5604-21. doi: 10.1021/acs.jmedchem.5b01599.
Diana Castagna 1,  David C Budd 2,  Simon J F Macdonald 2,  Craig Jamieson 1,  Allan J B Watson 1
Affiliations

Affiliations

  • 1 WestCHEM, Department of Pure and Applied Chemistry, University of Strathclyde , Glasgow, G1 1XL, U.K.
  • 2 Medicines Research Centre, GlaxoSmithKline , Gunnel Wood Road, Stevenage, Hertfordshire, SG1 2NY, U.K.
PMID: 26745766 DOI: 10.1021/acs.jmedchem.5b01599
Abstract

The autotaxin-lysophophatidic acid (ATX-LPA) signaling pathway is implicated in a variety of human disease states including angiogenesis, autoimmune diseases, Cancer, fibrotic diseases, inflammation, neurodegeneration, and neuropathic pain, among Others. As a result, ATX-LPA has become of significant interest within both the industrial and the academic communities. This review aims to provide a concise overview of the development of novel ATX inhibitors, including the disclosure of the first ATX clinical trial data.

Figures
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z